Healthcare & Life Sciences

Retension Pharmaceuticals

United States
Sign in to unlock

About

Retension Pharmaceuticals is developing RTN-001, an orally administered selective phosphodiesterase type 5 inhibitor designed to improve vascular function and treat cardiovascular and vascular disorders.

Explore Retension Pharmaceuticals's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing